8-K/A: OS Therapies Files Amendment to 8-K, Clarifies Financing Terms

OS Therapies Incorporated filed an amendment to its Form 8-K to include a side letter dated June 30, 2026, with Leonite Fund I, LP, clarifying terms related to a private placement transaction.

Summary

• This filing is an amendment (Amendment No. 1) to a previously filed Form 8-K by OS Therapies Incorporated.
• The amendment's purpose is to include a side letter dated June 30, 2026, between OS Therapies and Leonite Fund I, LP.
• This side letter was inadvertently omitted from the original Form 8-K filing.
• The side letter pertains to a private placement transaction previously described in the original Form 8-K.
• It clarifies specific terms related to a senior secured convertible promissory note and a common stock purchase warrant issued to Leonite Fund I, LP.
• Key clarifications involve the effective dates for adjustments related to 'Dilutive Issuances' under the note and warrant, with adjustments becoming effective on September 30, 2026, even if the dilutive event occurs earlier.
• The side letter also addresses carve-outs and exceptions in future financing terms, specifying that aggregated gross proceeds from multiple closings or tranches will not count towards the $5,000,000 threshold for certain provisions.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While it clarifies previously omitted information, it doesn't introduce new operational or financial performance data, nor does it resolve potential concerns about future dilution.

Positives

• Clarification of financing terms provides greater certainty for both OS Therapies and Leonite Fund I, LP.
• The amendment ensures all relevant transaction documents are now part of the public record.
• The agreement on effective dates for adjustments in the side letter offers a defined timeline for potential financial impacts.

Negatives

• The initial omission of a key document (the side letter) from the original filing suggests a procedural oversight.
• The specific terms regarding 'Dilutive Issuances' and the $5,000,000 threshold for future financings could indicate potential future dilution or limitations on future capital raises.

Risks

• Potential for future dilution to existing shareholders due to the 'Dilutive Issuance' provisions in the note and warrant.
• The clarification on future financing thresholds might limit the company's flexibility in raising smaller amounts of capital across multiple rounds.
• The need for an amendment highlights potential internal control or procedural weaknesses in document management.

Future Outlook

The filing itself does not provide a forward-looking outlook for the company's business operations. It solely focuses on amending a previous filing to include a side letter clarifying financing terms.

Management Comments

• The side letter clarifies that any 'Dilutive Issuance' shall constitute a Dilutive Issuance for all purposes under Section 2.2(b)(4) of the Note and Section 2(c) of the Warrant.
• Adjustments under these sections will not become effective on or prior to September 29, 2026, but will automatically become effective on September 30, 2026, for Dilutive Issuances occurring on or prior to September 29, 2026.
• Carve-outs or exceptions in the Transaction Documents relating to future financings of at least $5,000,000 in gross proceeds apply only to offerings with a single closing of at least $5,000,000, not aggregated proceeds.

Industry Context

StockSavvy.ai notes that amendments to SEC filings, especially those clarifying financing terms, are common as companies finalize complex transactions. The focus on 'Dilutive Issuances' and future financing thresholds is a critical aspect of capital markets activity for growth-stage companies like OS Therapies.

Related Party Transactions

• The filing details a side letter between OS Therapies Incorporated and Leonite Fund I, LP, a party to a securities purchase agreement, note, and warrant.

Stakeholder Impact

• Shareholders: Potential impact from future dilution as clarified by the 'Dilutive Issuance' terms and the $5,000,000 financing threshold. The clarification may reduce uncertainty.
• Investors (Leonite Fund I, LP): The side letter provides clarity on the terms of their investment, reducing ambiguity regarding adjustments and future financing conditions.
• Creditors: No direct impact mentioned in this amendment.

Next Steps

• The side letter clarifies that adjustments related to Dilutive Issuances will become effective on September 30, 2026.
• The company will need to adhere to the clarified terms regarding future financings of $5,000,000 or more.

Key Dates

Keywords

OS Therapies, 8-K/A, Amendment, Leonite Fund I, LP, Private Placement, Convertible Promissory Note, Warrant, Dilutive Issuance, Financing Terms, SEC Filing